Purchases are not available yet. You can browse the site and sign in.
Microdosing Afterglow: The Day After a Microdose · Microdosing College
Foundations
The Day After a Microdose: Afterglow, Carryover and Comedown
By Microdosing College Editorial·Last updated October 27, 2026·7 min read
The microdosing afterglow is the term most commonly used to describe a carryover sense of wellbeing, mental clarity, or emotional ease that some people report on the day after taking a microdose — a day when no new dose is consumed. It is one of the most frequently cited reasons that protocols such as the Fadiman schedule build in mandatory rest days rather than dosing every day. But the honest answer about what drives it is more complicated than the community consensus often suggests.
This article unpacks what the afterglow is, what the evidence actually shows, how it relates to tolerance and scheduling, and why expectancy is an unavoidable part of the story. For a broader look at the timeline of a single dose, see how long does a microdose last.
What people report on the day after dosing
In qualitative accounts and large online surveys, microdosers commonly describe the day after a dose as the most functional day of their cycle. The descriptions include easier access to a positive mood, reduced mental friction, a sense of openness, and — sometimes — a slight creative looseness that was less evident on the dosing day itself, when a mild sharpening or slight anxiety was present instead.
A 2023 systematic review by Evens and colleagues (Therapeutic Advances in Psychopharmacology) searched for controlled and observational evidence of these so-called subacute effects — defined as changes occurring 1 day to 1 month after a psychedelic dose. Across 48 studies involving 1,774 participants (spanning macrodoses as well as microdoses), they found a consistent pattern: participants reported psychological improvements in the days after dosing more reliably than purely on dosing days. Mood, openness, and self-reported wellbeing were the most common signals. However, the review also documented mild adverse subacute effects in some participants, including fatigue and emotional blunting, and noted that expectancy effects and the absence of blinded conditions in many studies make causal attribution difficult.
For context, most of the 48 studies in that review used full or moderate doses, not microdoses. Evidence specifically about the day after a microdose is still sparse, mostly drawn from naturalistic surveys and self-report diaries rather than controlled trials.
The pharmacological story: what might actually carry over?
Psilocybin itself is metabolised to psilocin and then cleared from the body within roughly four to six hours of a standard dose. At microdose levels, blood concentrations are lower and clearance is faster. By the morning after a microdose, there is almost certainly no active psilocin remaining in the bloodstream.
So what could produce a next-day effect? Several mechanisms have been proposed, none of them conclusively proven at microdose scale:
Downstream serotonergic activity. 5-HT2A receptor agonism from psilocin can trigger cascades — including BDNF expression and default mode network changes — that may outlast the drug's direct presence. These effects are better documented at higher doses; whether they occur meaningfully at sub-perceptual doses is not established.
Sleep effects. A controlled trial by Allen and colleagues (Translational Psychiatry, 2024) found that LSD microdoses added approximately 24 minutes of sleep the night after dosing, with no reduction on the dosing day. Better sleep is a plausible independent driver of next-day mood improvements — not strictly a drug carryover but a secondary consequence. Whether psilocybin microdoses produce similar changes has not been studied as rigorously. See microdosing sleep effects for more.
Tolerance dynamics. 5-HT2A receptors downregulate rapidly after psilocybin exposure, as documented in animal models (de la Fuente Revenga et al., ACS Chemical Neuroscience, 2022). Dosing on consecutive days would blunt effects — so the off-day is partly a pharmacological necessity regardless of any afterglow. Whether it also produces a subjective receptor-resensitisation signal is speculative.
Expectancy, set, and why the signal is hard to isolate
Any honest discussion of the afterglow must acknowledge the expectancy problem. Microdosing protocols ask people to dose on specific days and abstain on others. If you know today is your 'rest day after a dose,' you may unconsciously pay more attention to positive experiences and attribute them to the substance. This is not a character flaw — it is how human perception works, and it is why the self-blinding citizen-science study (Szigeti et al., 2021, eLife) found that placebo takers improved as much as active microdosers overall.
The 2023 systematic review by Evens et al. and the critical review by Rieser and colleagues (Current Opinion in Psychology, 2025) both emphasise this point. Rieser's team, reviewing 57 human studies, found a persistent divergence: observational and self-report studies tend to show benefit; blinded controlled trials show weaker or null effects. The afterglow sits squarely in the self-report tradition. That does not mean it is fake — but it means we cannot yet confidently separate pharmacological carryover from a well-placed placebo.
The 2024 controlled-trial review by Marschall and colleagues (Biological Psychiatry: CNNI) reviewed 12 controlled microdosing studies and found that acute effects were modest and inconsistent across studies. Subacute effects were rarely a primary outcome, making them even harder to assess. The authors called for longer-term, blinded study designs before conclusions can be drawn.
How the afterglow rationale shapes scheduling
Despite these caveats, the afterglow concept is doing real work inside most popular microdosing protocols. The Fadiman 1-day-on/2-days-off structure explicitly relies on the idea that the second day (the first off-day) carries residual benefit, and that by the third day the system is neutral and ready for the next dose. Every-other-day microdosing schedules compress this to alternating days on the same logic.
If the afterglow effect is partly or largely expectancy-driven, this does not necessarily make the protocol wrong — structured intention and attention are not nothing. But it does mean that the schedule should not be justified purely on pharmacological grounds. If you are tracking your own response, note that how long does a microdose last covers the direct pharmacological window, while the day after sits in territory that is harder to attribute.
Some practitioners suggest using off-days for practices that could plausibly synergise with any residual openness — journaling, movement, or deliberate rest — rather than leaving the window passive. See our guide to off-day practices for practical ideas. Whatever you do on those days, keeping a written log is the only practical way to distinguish your own signal from noise over time.
What to watch for: benefits, side effects, and red flags
The subacute effects documented in Evens et al.'s review were not all positive. A minority of participants reported fatigue, low mood, or emotional flatness the day after dosing — sometimes described as a 'comedown' rather than an afterglow. This is a genuine possibility worth tracking rather than dismissing.
Common self-reported next-day experiences (both directions):
The variability is large, and the direction a given person experiences appears to depend heavily on individual factors — baseline mood, sleep quality, stress load, and likely genetics. Rieser et al. (2025) flagged individual variability as one of the most under-studied aspects of microdosing research overall.
If you are consistently experiencing negative next-day effects, that is useful data. It may indicate the dose is too high (see signs your microdose is too high) or that microdosing is not well-suited to your current situation. Use the self-screener and, if you have a mental health history or take medication, speak with a clinician before continuing.
Key takeaways
The microdosing afterglow is a widely reported phenomenon with a plausible but unproven pharmacological basis. A 2023 systematic review found consistent subacute positive signals across dozens of studies, but the evidence is weakest at the microdose level, and expectancy effects remain a significant confounder. The day-after sleep improvement found in LSD microdosing trials (Allen et al., 2024) offers one concrete pathway worth tracking in your own journal.
Approach next-day experiences with the same sceptical honesty you would want applied to any self-report: the afterglow is real to many people, and genuinely uncertain in its origins. Both things matter. For questions about whether microdosing is appropriate for your situation, start with the screener.
The microdosing afterglow is a reported sense of improved mood, clarity, or emotional ease on the day after a microdose — when no new dose is taken. It is widely cited as the rationale for every-other-day schedules, but its pharmacological basis is not yet established in controlled studies.
Does psilocybin still affect you the day after a microdose?+
Active psilocin is typically cleared from the body within four to six hours of dosing. Any next-day experience is unlikely to involve direct drug action. Proposed mechanisms include downstream serotonergic changes, improved sleep quality, or expectancy effects — none have been conclusively demonstrated at microdose levels.
Can the day after a microdose feel negative — a comedown?+
Yes. The systematic review by Evens et al. (2023) found that while many people report positive subacute effects, a subset experience fatigue, mild low mood, or emotional blunting the following day. If you consistently feel worse the day after dosing, this may indicate the dose is too high or that microdosing is not suited to your current situation.
Why do microdosing schedules include days off?+
Off-days serve two purposes: they prevent rapid 5-HT2A receptor downregulation (tolerance), which would blunt effects if you dosed daily; and they are justified partly by the afterglow rationale — the idea that benefit carries over to the rest day. Both pharmacological tolerance and the afterglow concept support spacing doses at least every other day.
How much of the afterglow effect is placebo?+
This is genuinely uncertain. Self-blinding studies (Szigeti et al., 2021) found placebo and active groups improved similarly overall. The afterglow is largely studied through self-report, where expectancy effects are difficult to eliminate. Rieser et al. (2025) and Marschall et al. (2024) both note this as a key limitation of the existing evidence.
This guide is general educational information about microdosing, not medical advice and not a recommendation to use any substance. It can't account for your personal health. If you take medication or live with a mental-health condition, speak with a qualified professional before making any decision.
